GAMMA Investing LLC Purchases 49 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

GAMMA Investing LLC increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,533 shares of the company’s stock after buying an additional 49 shares during the period. GAMMA Investing LLC’s holdings in IDEXX Laboratories were worth $634,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of IDXX. Oddo BHF Asset Management Sas bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $1,128,000. American Trust acquired a new position in IDEXX Laboratories in the third quarter valued at approximately $757,000. Franklin Resources Inc. boosted its holdings in shares of IDEXX Laboratories by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock worth $675,259,000 after buying an additional 34,305 shares in the last quarter. Tidal Investments LLC grew its position in shares of IDEXX Laboratories by 7.6% during the 3rd quarter. Tidal Investments LLC now owns 6,310 shares of the company’s stock worth $3,188,000 after buying an additional 444 shares during the period. Finally, Sanctuary Advisors LLC increased its stake in shares of IDEXX Laboratories by 20.4% in the 3rd quarter. Sanctuary Advisors LLC now owns 3,288 shares of the company’s stock valued at $1,661,000 after acquiring an additional 558 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 1.6 %

Shares of IDEXX Laboratories stock opened at $415.53 on Friday. The company has a market capitalization of $34.03 billion, a P/E ratio of 40.07, a price-to-earnings-growth ratio of 3.94 and a beta of 1.36. The stock has a fifty day simple moving average of $424.43 and a 200 day simple moving average of $462.83. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. During the same quarter in the prior year, the business posted $2.53 EPS. The business’s revenue was up 6.6% compared to the same quarter last year. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IDXX. JPMorgan Chase & Co. cut their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Barclays cut their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Finally, Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $539.63.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares in the company, valued at $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.